FDA Advises Stronger Diabetes Drug Warning
Posted on: Wednesday, 15 August 2007, 09:12 CDT
The U.S. Food and Drug Administration said manufacturers of certain type 2 diabetes drugs have agreed to add a stronger heart failure warning on drug labels.
Heart failure is a condition that occurs when the heart does not adequately pump blood. The FDA said the information will be included in the form of a boxed warning -- the FDA's strongest form of a warning -- emphasizing the drugs might cause or worsen heart failure in some patients.
The FDA said the warning involves the thiazolidinedione class of anti-diabetic drugs. The products include the brands Avandia, Actos, Avandaryl, Avandamet and Duetact -- all manufactured by GlaxoSmithKline and Takeda.
This new boxed warning addresses FDA's concerns that &133; these drugs are still being prescribed to patients without careful monitoring for signs of heart failure, said Dr. Steven Galson, director of the FDA's Center for Drug Evaluation and research.
The strengthened warning advises health care professionals to observe patients carefully for the signs and symptoms of heart failure, including excessive and rapid weight gain, shortness of breath, and edema after starting drug therapy. The FDA said the use of the drugs by such patients should be reconsidered.
Source: United Press International
Related Articles
- FDA: No Epilepsy Drug Black Box Warnings
- J&J Unit Orders Heart Failure Drug Test
- More Warnings Urged for ADHD Drugs
- U.S. Advisors Recommend Safety Warnings Against Attention Deficit Drugs
- FDA Approves New Drug to Treat Chronic Angina
- Heart Failure Drug Maker Relays New Deaths
- Heart Failure Drug for Blacks a Good Deal
- Abbott heart failure drug effective in trial
- Heart Failure Drug Stirs Controversy
- FDA Advisers: Cholesterol Drug Shouldn't Be Sold Over Counter
 |
 |
User Comments (0)
RSS Feeds